US 11,994,510 B2
Diagnosis and treatment of Fusariosis and Scedosporiosis
Sophia Koo, Brookline, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US)
Appl. No. 16/341,265
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Oct. 11, 2017, PCT No. PCT/US2017/056107
§ 371(c)(1), (2) Date Apr. 11, 2019,
PCT Pub. No. WO2018/071519, PCT Pub. Date Apr. 19, 2018.
Claims priority of provisional application 62/406,441, filed on Oct. 11, 2016.
Prior Publication US 2020/0041484 A1, Feb. 6, 2020
Int. Cl. G01N 33/497 (2006.01); C12Q 1/04 (2006.01)
CPC G01N 33/497 (2013.01) [C12Q 1/04 (2013.01); G01N 2033/4977 (2013.01)] 10 Claims
 
1. A method for diagnosing and treating a subject with scedosporiosis, the method comprising:
obtaining a sample comprising breath of a subject suspected of comprising Scedosporium species fungi isolated from the subject;
detecting the presence of two, three, or more volatile organic compounds (VOCs) produced by the Scedosporium species in the sample comprising breath from the subject suspected of comprising Scedosporium isolated from the subject, wherein the VOCs are selected from the group consisting of (a) 1H-Indene, 2,3,3a,4-tetrahydro-3,3a,6-trimethyl-1-(1-methylethyl)-, (b) β-guaiene, (c) β-longipinene, (d) β-gurjunene, and (e) isocomene;
diagnosing the subject as having scedosporiosis when there are two, three or more of the VOCs present in the sample; and
administering an antifungal treatment to the subject diagnosed as having scedosporiosis.